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Prostate cancer is the second common cancer in men worldwide. The prevention of prostate cancer remains a challenge to
researchers and clinicians. Here, we review the relationship of vitaminD and sunlightto prostate cancer risk. Ultraviolet radiation
of the sunlight is the main stimulator for vitamin D production in humans. Vitamin D’s antiprostate cancer activities may be
involved in the actions through the pathways mediated by vitamin D metabolites, vitamin D metabolizing enzymes, vitamin D
receptor (VDR), and VDR-regulated genes. Although laboratory studies including the use of animal models have shown that
vitamin D has antiprostate cancer properties, whether it can eﬀectively prevent the development and/or progression of prostate
cancer in humans remains to be inconclusive and an intensively studied subject. This review will provide up-to-date information
regarding the recent outcomes of laboratory and epidemiology studies on the eﬀects of vitamin D on prostate cancer prevention.
1.Introduction
The World Health Organization (http://globocan.iarc.fr/
factsheets/cancers/prostate.asp) indicates that prostate
cancer is the second most frequently diagnosed cancer in
men (903,000 new cases) and has about 258,000 deaths of
this cancer worldwide in 2008. The highest incident rates
are among the countries of Australia/New Zealand Western,
Northern Europe, and Northern America, and the lowest
age-matched incidence rates are those in South-central Asia.
In the USA alone, the American Cancer Society (http://www
.cancer.org/Cancer/ProstateCancer/DetailedGuide/prostate-
cancer-key-statistics) estimated death and newly diagnosed
cases of prostate cancer were 32,050 and 217,730 men,
respectively, in year 2010. Moreover, in USA, the total
medical expenditure for prostate cancer treatment was
estimated as $1.3 billion in year 2000, which represents a
30% increase compared to that in 1994. In year 2004, 2.3
billion was estimated for prostate cancer alone [1]. As being
a prevalent cancer disease in men, current total cost for PCa
prostate cancer treatments in USA would much exceed $2.3
billion.
Until now, etiology of prostate cancer is still largely
unknown. However, it has been suggested that there are
several potential risk factors that may change incidence rates
of this cancer, including diet/nutrition, physical activities,
and others [2, 3]. Epidemiologic and laboratory studies
in nutrition and diet as modiﬁable risk factors seem to
build strong concepts of cancerc h e m o p r e v e n t i o n ,as t r a t e g y
seeking the reduction of cancer risk by the use of chemical
agents [3–7]. Conceptually, these agents may be used to
prevent, delay, or reverse cancer formation as well as
progression. Indeed, due to its long latency of disease onset
and high incidence and mortality rates, prostate cancer
should be an ideal target for chemoprevention. Proper diets
may eventually reduce 50–60% incidence of prostate cancer
and many other cancers. Therefore, the potential impact of
prostate cancer chemoprevention could be enormous, with
respect to prostate cancer patients, in saving life, increasing
quality of life and reducing community ﬁnancial burden.
One such dietary factor having anticancer properties
is vitamin D. Vitamin D is very important for normal
physiology [8, 9]. The natural way to obtain vitamin D in
t h eb o d yi sb ye x p o s i n gs k i nt os u n l i g h t[ 9, 10]. Avoiding
skin carcinogenesis and with many other reasons, skins
may not receive suﬃcient amounts of sunlight exposure for
producing enough vitamin D; fortiﬁed vitamin D in some
commonly consumed foods or supplement forms has been2 Advances in Preventive Medicine
used for human health purposes. Evidence suggests that
vitamin D in our body may be negatively associated with the
development and/or progression of several cancers includ-
ing prostate cancer [10, 11]. As discussed below, although
experimental results from in vitro and preclinical models
showed strong support of antiprostate cancer activities of
this vitamin, epidemiological studies and clinical trials on
human subjects hardly produce unanimous agreements for
the potential of antiprostate cancer eﬃcacy. In this article,
we will present recent ﬁndings of laboratory results in
supporting of vitamin D’s antiprostate cancer eﬀects and
discussconﬂicting epidemiologicalﬁndings ofthe vitamin in
human subjects.
2.VitaminDMetabolism
Although the previtamin D 7-dehydrocholesterol was
thought to be produced in the gut wall cells and transported
to skin cells, actually skin cells can synthesize their own 7-
dehydrocholesterol, which in turn is converted to a provita-
min D,cholecalciferol, orvitamin D3, by isomerizationupon
ultraviolet B (UVB) radiation of sunlight in epidermis [12–
14].FurtherphotoreactionofvitaminD3 by UVBabsorption
may generate inactive metabolites. Vitamin D3 is metabo-
lized to calcidiol 25(OH)D3 in the liver by the mitochon-
drial sterol 27-hydroxylase (27-hydroxylase; (CYP27A1) and
converted to a biologically active vitamin D, calcitriol/1,25-
dihydroxyvitamin D3 (1,25(OH)2D3), by 1α-hydroxylase
(CYP27B1) in the kidney and other tissues including the
prostate [15–18]. Usually circulating 25(OH)D3 level is used
to determine vitamin D nutritional status, because it is
a predominant form of vitamin D in blood stream and
has a much longer half life than that of 1,25(OH)2D3
(i.e., 15 days versus 15 hours) [19]. Importantly, its serum
concentrations may be correlated with total vitamin D
levelsfrombothendogenousproductionanddietary uptakes
[20–23]. However, 25(OH)D3 is by no means a perfect
marker for active vitaminD3 status. For example, it is
questionable whether measuring 25(OH)D3 can represent
the bioavailability of vitamin D2 (ergocalciferol, a vitamin
D proform derived from fungus products) versus vitamin
D3. Some studies [24, 25]b u tn o to t h e r[ 26] showed that
vitamin D3 supplementation could increase 25(OH)D3 to
higher levels than the use of vitamin D2. In fact, blood
25(OH)D3 levels can be aﬀected by substrate availability
through adiposity sequestration, skin pigmentation, physical
activity [20, 27, 28], and the consumption of dietary factors
such as genistein and folate [29–32].
As indicated above, 25-hydroxyvitamin D3 1-α hydrox-
ylase or 1-α hydroxylase (CYP27B1) is also expressed in
the prostate, meaning that prostate cells can produce the
active form of vitamin D3. This enzyme activity has been
demonstrated in human primary prostatic cell cultures
as well as prostate cancerous cell lines. Obviously, this
enzyme may have a role in negatively regulating prostate cell
proliferation [33]. Human prostatic cancerous cells seem to
have reduced activity or expression levels of 1-α hydroxylase
compared to normal or benign prostatic cells, therefore,
losing ability to synthesize 1,25(OH)2D3 [34].
There are not many studies demonstrating intraprostatic
concentrationsofvitamin Dmetabolites. One report showed
that prostatic 1,25(OH)2D3 levels were higher than that
in blood circulation in domestic pigs [35]. Other study
found that within 24 hours of intravenous injection of
1,25-dihydroxyvitamin D3, less than 1% of the vitamin D
in blood was detected in rat prostate tissues [36]. The
third study also demonstrated the potential intraprostatic
vitamin D metabolism in human prostate [37]. 25OHD3,
24,25(OH)2D3, and 1,25(OH)2D3 were all detected in
prostate tissues obtained by prostatectomy. This particular
study with a very small sample size seemed to suggest that
levels of 24,25(OH)2D3 and 1,25(OH)2D3 in the prostate
were higher than in serum tested.
One possible mechanism for the reduced expression
of 1-α hydroxylase may be due to hypermethylation or
repressive histone modiﬁcation of its promoter, which could
implicate prostate cancer development and progression [38–
40]. Other possibility includes posttranslational suppression
of enzymatic activity [39, 41].
It was reported that 25(OH)D3 but not 1,25(OH)2D3
can enhance the expression of 1-α hydroxylase in cultured
prostatic cells [42]. Because of this, the authors of the studies
suggested that high concentrations of 25(OH)D3 might be
used as antiprostate cancer agent instead of large doses of
1,25(OH)2D3 to avoid hypercalcemia side-eﬀects.
Opposed to 1-α hydroxylase, 25-hydroxyvitamin D3 24-
hydroxylase (CYP24A1) is a catabolic enzyme causing inac-
tivation of 1,25(OH)2D3 that might implicate resistance to
antiproliferation eﬀects of 1,25(OH)2D3 [43, 44]. However,
some studies suggested that this 24-hydroxylase is downreg-
ulated in prostate tumor cells [45]. By examining 30 paired
human prostate benign and primary malignant tissues and
three prostate cancer cell lines, the study demonstrated that
a signiﬁcant number of malignant tissues had lower mRNA
expression and higherpromotermethylation levelsofthe24-
hydroxylase comparedtothoseofbenigntissues. Inaddition,
two out of three cancer cell lines tested had high methylation
and low expression levels of the enzyme gene. In these two
cell lines, that is, PC-3 and LNCaP, treatments with the DNA
methyltransferase inhibitor 5-aza-2 -deoxycytidine and/or
the inhibitor of histone deacetylases trichostatin A can
activate the expression ofthis gene, suggesting that promoter
DNA methylation, and repressive histone modiﬁcations play
roles in repressing its expression [45]. Intriguingly, it has
been shown that 1,25(OH)2D3 can induce the expression of
the 24-hydroxylase in PC-3, LNCaP, DU145, and primary
prostatic stromal cells, perhaps through (VDR) to bind a
VDR responsive element (VDRE) [43–45]. A recent study
found that a genetic single nucleotide polymorphism in the
VDRE of the 24-hydroxylase promoter could reduce the
expression and activity of this enzyme [46]. In addition,
1,25(OH)2D3 may modulate the expression of alternative
splicing forms of the 24-hydroxylase in prostate cancer cells
[47]. The signiﬁcance of the splicing forms in prostate
cells remains unclear. Not surprisingly, the 24-hydroxylase
activity in prostate cancer cells could be inversely related
to inhibitory proliferation eﬀects of 1,25(OH)2D3 [44]. It
was reported that the androgen dihydrotestosterone wasAdvances in Preventive Medicine 3
able to inhibit the inducible eﬀect of 1,25(OH)2D3 on 24-
hydroxylase expression and activity in prostate cancer cells
[48, 49]. This seems to indicate that a cross-talk of androgen
receptorandVDRwasatwork.Furthermore,thesame group
oftheauthorsshowedthatbysuppressingthe24-hydroxylase
androgens can largely increase antiproliferative eﬀects of
1,25(OH)2D3. Since prostate stroma may provide an impor-
tant microenvironment for prostate cancer development,
these authors also showed that retinoic acid via retinoic acid
receptor alpha inhibited the 24-hydroxylase expression in
human prostatic stromal cells P29SN and P32S [50]. When
treated with both retinoic acid and 1,25(OH)2D3.s y n e r gi s t i c
growthinhibitory eﬀects were observed in these cells.
Thus the above studies clearly demonstrated that the
24-hydroxylase is a useful target for increasing anticancer
eﬃcacy of vitamin D. Genistein, a soy isoﬂavone, was
shown to be capable of enhancing antiproliferative eﬀect of
1,25(OH)2D3 on DU145 cells by repressing the expression
of the 24-hydroxylase [51, 52]. Moreover, genistein in
nanomolar concentrations was able to inhibit enzymatic
activity of the 24-hydroxylase as well as to upregulate the
expression of VDR. Recent studies [53, 54]r e p o r t e dt h a ta
nonspeciﬁc, broad inhibitor of cytochrome P450 enzymes,
ketoconazole or a speciﬁc 24-hydroxylase inhibitor, RC2204
was used in PC-3 cell culture or xenograft, respectively, to
demonstrate that they can suppress 24-hydroxylase activities
and enhance antitumor growth potency of 1,25(OH)2D3.
3.ActionofVDR inProstateCancerCells
Anticancer activities of vitamin D have been suggested to act
m a i n l yt h r o u g hi t sn u c l e a rr e c e p t o ro rV D R .T h eV D Ri sa
member of nuclear receptor super family, whose functions
act as ligand-dependent transcription factor in the nucleus
[54–56]. In addition, upon ligand activation, this receptor
requires to form a heterodimer with the retinoid X receptor
(RXR) in order to bind a speciﬁc genomic DNA sequence,
that is, a VDRE to activate or repress gene expression [54–
56]. RXR of the VDR heterodimer may be subjected to
phosphorylation by prolonged activation of the mitogen-
activatedproteinkinasepathway,resultingintheimpairment
ofVDR-mediated prostatecellgrowthinhibition eﬀects[57].
Recently, a report showed that the vitamin D receptor can
form a heterodimer with retinoic acid receptor gamma [58].
AlthoughithasbeenshownthatandrogenreceptorandVDR
may cross talk each other in their pathways [49, 59, 60],
the two receptors probably do not have direct interactions.
It has been reported that the expression of VDR can be
regulated by several hormones including androgens, vitamin
D, parathyroid hormone, retinoic acid, and glucocorticoids
[55, 56]. However, the regulation of the basal line expression
of the receptor is not well studied. Besides, the genomic
gene regulation eﬀects, through a so-called nongenomic
mechanism, the same receptor activated by vitamin D in
the plasma membrane may also have rapid modulation
eﬀects on cellular functions [55, 56, 61]. Both genomic
and nongenomic eﬀects of VDR have been demonstrated in
prostate cells [43, 62, 63]. The question also arises if there is
a separate membrane VDR. According to other investigators
[64–66], protein disulﬁde isomerase family A, member 3
(PDIA3) has been identiﬁed as a membrane associated,
1,25(OH)2D3 binding protein/receptor that may exhibit
some rapid nongenomic actions of 1,25(OH)2D3.P D I A 3
with 1,25(OH)2D3 binding ability has recently been detected
in several human prostate cell lines [66]. The signiﬁcance
of PDIA3-mediated 1,25(OH)2D3 action in prostate cancer
cells requires further studies.
Vitamin D mainly via VDR’s genomic eﬀects may
suppress prostate cancer cellular dysfunctions including the
inhibition of cell proliferation, cell cycle progression, cell
invasiveness, angiogenesis, or induction of cell diﬀerentia-
tion and apoptosis [67, 68]. These prostate cancer cellular
functions can be altered by the ability of ligand-activated
VDR to change the expression and/or functions of many
downstream key genes, for example, decrease of c-Myc
[69, 70], telomerase [71], BCL-2 [72], α6a n dβ4 integrins
[73], cyclin-dependent kinase 2 (CDK2) activity [74], and
phosphorylation of the retinoblastoma protein [75], and
increase of the (CDK) inhibitors p21Waf/Cip1 and p27Kipl
[74, 76–78] and growth arrest and DNA damage-inducible
gene gamma (GADD45γ)[ 79]. In addition, active vitamin
D3 and its analogs may increase the expression of E-cadherin
[78] and the activity of tissue inhibitor of metalloproteinase-
1 (TIMP-1) as well as decrease the expression and activity
of MMP-9 [80], thereby decreasing invasive and metastatic
potentials of prostate cancer cells studied.
Many angiogenic and proinﬂammatory regulators may
play crucial roles in prostate tumorigenesis and progression
[81–84]. It has been shown that 1α,25-dihydroxyvitamin
D3 [1,25(OH)2D3] inhibits tumor angiogenesis in vitro and
in vivo [85]. Interleukin 6 (IL-6) is one such molecule
that may implicate in prostate cancer progression. Calcitriol
was shown to inhibit tumor necrosis factor α mediated
increase of IL-6 in primary prostate cells [86]. Another
pro-inﬂammatory cytokine interleukin 8 (IL-8) may also
have angiogenic and tumorigenic potentials in prostate
cancer [83]. Calcitriol can lower the IL-8 levels in two
immortalized human prostateepithelialcell lines(HPr-1and
RWPE-1) and three prostate cancer cell lines (i.e., LNCaP,
PC-3, and DU145) [87], by reducing NFκBp 6 5n u c l e a r
translocation and gene transcription of IL-8. Calcitriol may
have radiosensitization eﬀects on prostate cancer cells by
suppressing ion radiation-mediated activation of the NFκB
relatedRelB,which subsequentlyreducesthetranscriptionof
manganese superoxide dismutase (MnSOD) [88]. Increased
antioxidant activities of MnSOD can cause radiation resis-
tant. It was reported that calcitriol reduces the protein and
mRNA expressions of both the hypoxia-inducible factor
(HIF)-1α subunit and the vascular endothelial growth factor
(VEGF) in several human cancer cells including prostate
cancer cells under hypoxia conditions [89]. Furthermore,
using transgenic adenocarcinoma of the mouse prostate
(TRAMP)-2 tumors transplanted into either wild-type or
VDR knockout (KO) mice with calcitriol treatments, it was
found that tumors in the KO mice were larger than that
in wild-type mice, suggesting ligand-induced VDR growth
inhibitoryeﬀectsinwild-typemice.Similarly,enlargedblood
vessels and increased vessel volume in TRAMP-2 tumors4 Advances in Preventive Medicine
were found in the VDR knockout mice, suggesting that
antitumor angiogenesis was directly aﬀected through VDR
and calcitriol at tumor sites. HIF-1α, VEGF, angiopoietin 1,
and platelet-derived growth factor-BB levels were increased
in tumors from KO mice [90]. The importance of VDR in
negatively regulating prostate cancer progression is further
conﬁrmed in the LPB-Tag model of prostate in VDR
knockout versus VDR wild-type mice [60].
Vitamin D may also inﬂuence genes in the metabolism
of prostaglandins (PGs) that can induce the inhibition of the
expression ofthePGsynthesizing cyclooxygenase-2(COX-2)
and the PG receptors EP2 and FP, and increased expression
of PG inactivating 15-prostaglandin dehydrogenase [67, 91–
93]. The alteration of these gene expressions would decrease
the cell proliferative stimulus of PGs in prostate cancer
cells.
4.SunlightExposureand ProstateCancer
Vitamin D deﬁciency or insuﬃciency has become a public
health concernin large proportions of the populationsin the
United States and Northern European countries especially
amongethnicgroupswithdarkskin,andotherssuchasthose
with physical inactive and little sun exposure. As mentioned
above, sunlight exposure may increase vitamin D synthesis
in the skin which has been thought to be beneﬁcial to
protect from some types ofcancer, including prostate cancer.
Of course, prolonged sunlight or UVB exposure without
adequateskinprotectioncan cause skincancer. Indeed, there
are many ecological and observational studies including
case-control and prospective studies [94–106]s h o w i n ga
high degree of consistent results that sunlight exposure is
inversely associated with prostate cancer risk. Geographic
regions with less sunlight exposure seem to be related to
an increased prostate cancer mortality [96, 97]. Studies
[102, 103] also showed that patients diagnosed with prostate
cancer in summer may havehigher survival rates than thatof
patients in the winter due to seasonal UV irradiance levels.
There are epidemiological studies [101, 107–109] suggesting
that the ethnic groups with dark skin could be associated
with high prostate cancer risk because high skin pigments
may reduce the absorption of UV radiation. However, a
study reported that black men did not increase their prostate
cancer risk in terms of sunlight exposure when compared to
white counterparts [110]. There is epidemiological evidence
that shows skin cancer patients may have reduced risk
for procuring certain types of secondary cancer including
prostate cancer [111–113]. However, the result of a study
did not support the notion that sunlight induced skin cancer
can protect against prostate cancer risk [114]. Although
there are overwhelming number of studies indicating that
UVB exposure from sunlight consistently reduce risk of
prostate cancer development and progression, yet not every
study fully supports this idea. For instance, a population-
basednestedcase-controlstudyandmeta-analysis [115]on ly
provided a limited support for the eﬀect of sunlight on
reducing prostate cancer. Also, a study showed contradictory
r e s u l t st h a th i g hl e v e l so fU V Re x p o s u r em a yb ep o s i t i v e l y
associated with the risk of prostate cancer mortality [116].
Another group of investigators [117, 118] used their ecolog-
ical approach to conduct a multicountry study consisting of
33 countries worldwide to evaluate the eﬀect of residential
UV exposure on cancer incidence. The study results did not
prove that sunlight/UV exposure could decrease the risk of
various cancers including prostate cancer. The investigators
of this study emphasized the importance of the control for
various confounders that might have been overlooked in
other studies.
5.CirculatingVitaminDand
Prostate CancerRisk
Unlike most of sunlight exposure studies, linking circulating
vitamin D levels or vitamin D uptakes with the reduction of
prostate cancer risk has not been very successful. Of course,
there are some studies [119–122] seeming to support the
notion that high levels of serum vitamin D have protection
eﬀects against prostate cancer. A US study indicated that
serum 1,25 vitamin D3 was negatively associated with
prostate cancer restricted to men above median age of
57 years [119]. In a Fannish study with 13yr followup
of about 19,000 men, the authors found that low serum
25(OH)D3 concentrations were associated with high risk
of earlier exposure to and more aggressive prostate cancer
[120]. In addition, there are two more recent reports [121,
122] with an 18yr or a 44.0 month median time followup,
respectively, suggesting that both circulating 25(OH)D3 and
1,25(OH)2D3 or 25(OH)D3 alone at median or higher
than medium levels have lower risk for prostate cancer
progression.
In fact, there are a good number of studies demon-
strating no inverse relationship between circulating vitamin
D metabolite levels and risk of prostate cancer [123–129].
For example, a very recent meta-analysis study [127]o f
relationship of serum 25-hydroxyvitamin D3 levels with col-
orectal, breast and prostate cancer and colonic adenoma was
reported, showing, although there was a consistent inverse
relationship between circulating vitamin D metabolite levels
and colorectal cancer, no support for an association for
breast and prostate cancer was found. Another recent nested
prospective case-cohort study examined older men (65 or >)
participating in the multicenter Osteoporotic Fractures in
Men study for serum 25-OH vitamin D3 levels [128]. In
this prospective cohort, the authors concluded that there
was no association of serum 25-OH vitamin D3 levels with
subsequent prostate cancer risk. A large nested case-control
study [119] with a European population [129]i n d i c a t e d
no beneﬁcial eﬀects of blood vitamin D levels for reducing
prostate cancer risk. Another recent large prospective study
[130] also did not show that vitamin D had eﬀects on the
reduction of prostate cancer risk. On the other hand, the
same report stated that higher blood 25(OH)D3 levels could
be related to increased risk of aggressive prostate cancer.
A longitudinal nested case-control study was performed on
Nordic men consisting of [131] 622 prostate cancer cases
and 1,451 matched controls for serum 25(OH)D3 levels.
Intriguingly, the study revealed a U-shaped relationship of
prostate cancer risk and 25(OH)D3 levels, namely, bothAdvances in Preventive Medicine 5
low (≤19nmol/L) and high (≥80nmol/L) 25(OH)D3 serum
levels showed positive association with prostate cancer risk,
whereas normal average serum concentrations of 25(OH)D3
(40–60nmol/L) gave the lowest risk of prostate cancer.
It may be worth mentioning that a nested case-control
study [132] in the Health Professionals Follow-up Study was
designed to determine the relationship of plasma 25(OH)D3
and 1,25(OH)2D3 with prostate cancer risk. Although it was
found that there were no statistically signiﬁcant diﬀerences
between the two plasma vitamin D metabolites and the
overall prostate cancer risk, a signiﬁcant inverse association
existedbetween 25-hydroxyvitamin Dand advancedprostate
cancerwhen comparingquintile4orquintile5tothebottom
quintile. Moreover, when men who were clinically deﬁcient
eithervitaminDmetabolitecomparedtothose who were not
deﬁcient, deﬁcient group showed a 38% lower risk of total
prostate cancer, a 58% lower risk of poorly diﬀerentiated
prostate cancers, and a 49% lower risk of aggressive prostate
cancers. An earlier study also reported that only older
group (>61 years) with plasma 25(OH)D3 lower than the
median showed a 57% reduction of cancer risk [133]. These
unexpected results warrant further investigation.
Recent studies also could not ﬁnd any association of
vitamin D uptake with prostate cancer risk [134, 135]. With
a mean followup of 8 years, examining men involved in the
Multiethnic Cohort Study (1993–2002) using quantitative
food frequency questionnaire revealed that there was no
signiﬁcant association between calcium and vitamin D
intake and risk of prostate cancer. In the Prostate Cancer
Prevention Trial (United States and Canada, 1994–2003)
with 9,559 participants, dietary or supplemental intakes of
vitamin D as well as many other factors analyzed did not
show any signiﬁcant correlation with prostate cancer risk.
A meta-analysis of many observational studies regarding
dairy products, calcium, and vitamin D intake and the risk
of prostate cancer was also conducted [136]. This study
concludedthat there was no signiﬁcant association of dietary
vitamin D uptake with the cancer risk.
6.GeneticVariationsinVitaminD Signaling
PathwaysandProstateCancerRisk
Since expression and functions of VDR, related vitamin D
metabolic enzymes and vitamin D signal downstream genes
are associated with vitamin D’s action, genetic variation such
as the single nucleotide polymorphisms (SNP)in these genes
may have impact on vitamin D action in cancer cells. There-
fore, analysis of the correlation of these polymorphisms with
cancer risk would be highly meaningful. Among more than
470 polymorphisms in the VDR gene [11, 17], there may be
six polymorphisms including the Fok1, Cdx2, Bsm1, Apa1,
and Taq1 SNPs, and Poly(A) microsatellite to be frequently
studiedinrelation torisk ofcancerincludingprostatecancer.
The ﬁve SNPs mentioned above are usually detected
by using restriction fragment length polymorphism or
direct sequencing, and the PolyA microsatellite at the 3 -
untranslated region (3 UTR) of the VDR gene is measured
with variable number of tandem repeat. These polymor-
phisms are located in 5 regulatory, coding, intron, or 3 UTR
of the VDR gene. The functionality of these polymorphisms
used in epidemiological and observational studies for cancer
risk may havebeensomewhat demonstrated byexperimental
approaches yet not completely resolved. For instance, Fok1,
located in the exon 2, consists of a T to C change resulting
in a longer protein translation (ﬀ versus FF). The short VDR
protein (i.e., 424aa) encoded by the Fok1 FF genotype has a
higher transcriptional activity than the long ﬀ protein (i.e.,
427aa) [136–139]. Interestingly, it was also reported that
individuals with ﬀ genotype may be associated with lower
serum 25(OH)D3 levels than those in individuals with FF
genotype [140]. For Cdx2 polymorphism, it has a change
from G to A in the binding site for an intestinal-speciﬁc
transcription factor, CDX2,within the VDR promoter [141],
the G allele of the Cdx-2 binding element has a signiﬁcantly
lower electrophoretic gel mobility shift assay activity and a
lower transcription assay activity than that of the A allele.
Although the PolyA microsatellite polymorphism has been
suggested to be important for mRNA stability, studies show
inconsistent conclusions, in which a report showed that the
length of the UTR has no eﬀect on mRNA stability [142],
but other demonstrated that it has stability eﬀects when
interacting with Fok1 F allele [139]. Both Bsm1 and Apa1
SNPs are located in the intron near exon 9, and Taq1 SNP is
located at exon 9 (which contains the 3 UTR). The potential
function roles of these three SNPs in the regulation of VDR
mRNA expression were examined brieﬂy, but no conclusive
results were produced [142–145].
Indeed, genetic heterogeneity eﬀects of vitamin D sig-
naling related genes, especially the VDR gene, have been
attractive research subjects for cancer risk studies and poten-
tial applications in cancer prevention strategy. Although
there are many of this type of epidemiological analyses
[106, 146–172]a sl i s t e di nTable 1, the apparent question is
whethergeneticvariantsofthosegenesinvolvedinvitaminD
pathways have real eﬀects on prostate cancer risk. However,
as shown in Table 1, the outcomes remain inconsistent and
perhaps conﬂicting and require further studies.
7.ConcludingRemarks
Although in vivo and in vitro laboratory studies pro-
vide strong evidence in supporting that vitamin D via
VDRpossesses antiprostatecanceractivities, epidemiological
studies have not shown consistent results for vitamin D’s
antiprostate cancer activities. Among many epidemiologi-
cal studies, especially those studies with measuring blood
vitamin D levels produced the least overall supporting
evidence for the antiprostate canceractivities. One drawback
of this type of studies is that the designs mainly relied on
one measurement of serum/plasma vitamin D metabolites
without multiple measurements in an adequate follow-up
time. The conclusion from these epidemiologic studies for
prostate cancer as well as other cancers are also reﬂected in
the Institute of Medicine’s 2011 report on dietary reference
intakes for calcium and vitamin D [9] which could not
make any conclusion if vitamin D has anticancer activities
in humans. However, the inconsistency of outcomes of
the epidemiologic studies may still provide a great deal of6 Advances in Preventive Medicine
Table 1:Summaryofoutcomesof28studies onthe associationofanalysisofpolymorphismsinvitaminD signalrelated genes withprostate
cancer risk.
Gene(s) Polymorphism(s) Case/control Results
(1) VDR Taq1 108/170 The tt genotype reduced cancer risk compared to the
Tt or TT genotype [146]
(2) VDR & AR AR CAG repeat and
VDR PolyA 57/169 The short CAG or long PolyA increased cancer risk
and both increased risk of advanced cancer [147]
(3) VDR BsmI, ApaI, and Taq1 222/128
A Japanese population
Only BsmI BB or Bb genotype was associated with
one-third of the risk of prostate cancer in a Japanese
population [148]
(4) VDR BsmI, ApaI, and Taq1 81 familialcases/105
A Japanese population No association[149]
(5) VDR F o k 1 ,B s m I ,T a q 1 ,a n d
PolyA
A meta-analysis of 14
studies No association[150]
(6) VDR FokI, BsmI, ApaI, TaqI,
and PolyA
African Americans
(113/121)
Whites (232/171)
No associationbut Fok1 FF genotype was associated
with cancer risk in young African American [151]
(7) VDR Apal and Taql 165/200
A Brazilian population No association[152]
(8) VDR BsmI, FokI, and PolyA 559/523
No associationwith overall cancer risk, but the BsmI
bb was associated with a modest risk increase of
localized prostate cancer compared to the BB
genotype [153]
(9) VDR BsmI, ApaI, and TaqI 160/205
A Taiwanese population
No overall cancer risk associationwith ApaI and TaqI.
But the Bsm1 BB and Bb versus the bb genotypes were
negatively associated with risk of cancer [154]
(10) VDR BsmI and TaqI 428 white men and 310
African-American men
No associationwith overall cancer risk except that the
Bsm1 B allele was inversely associated with recurrence
of locally advanced cancer among white men [155]
(11) VDR CDX-2, Fok1, and Taq1 368 cancer/243 BPH
CDX-2 GA and AA and Fok1 ﬀ were associated with
increased prostate cancer risk in men with UVR
exposure above the median, but genotype
combinations such as GGTT and FFTT were
associated with reduced risk in the higher UVR
exposure group [106]
(12) VDR C d x 2 ,F o x 1 ,T a q 1 ,a n d
Bgl II 450/455
FokI FF or Ff, TaqI tt, and BglI BB genotypes not
Cdx2 genotypes may signiﬁcantly protect against
cancer progression with high sun exposure [156]
(13) VDR Fok1 128/147
An Indian population
Only the FF genotype showed an increased cancer risk
[157]
(14) VDR FokI and BsmI 812/713
An Australian population
These two SNPs had no eﬀect on prostate cancer risk
[158]
(15) VDR,
VDBP
Novel sequence
variations in the two
promoters
165/324
African-American men
A novel VDR-5132 T/C SNP (i.e., CC genotype) was
found to increase cancer risk in African-American
men [159]
(16) VDR T a q I ,B s m I ,A p a I ,F o k I ,
and Poly(A)
A meta-analysis of 26
studies No association[160]
(17)
VDR,
CYP27A1,
CYP24A1
38 SNPs 630/565
Only two VDR SNP loci, rs2107301, and rs2238135,
with TT and CC genotypes, respectively, had a 2- to
2.5-fold increased risk of prostate cancer compared
with the respective homozygoteCC and TT alleles
[161]
(18) VDR Fok1 1,066/1,618
The Fok1 ﬀ genotype was found to increase cancer
risk when 25(OH)D levels were lower than the
median [162]Advances in Preventive Medicine 7
Table 1: Continued.
Gene(s) Polymorphism(s) Case/control Results
(19) VDR
SNPs in haplotype
block subregions C2
and C1
430 cancer/430 BPH
UK men
Haplotype block C including
G(3436)-A(3944)-C(20965)-C(30056),(G or
C)-A-C-C, and G-A-(C or T)-C was found
signiﬁcantly to increase cancer risk in men with very
low UVR exposure [163]
(20) VDR Apa I, BsmI, and Taq I 133/157
a Turkish population
Prostate cancer risk was found to be increased in those
whose genotypes were either the Aa or aa compared to
those with the AA type [164]
(21) VDR,
SRD5A2
Fox1 or Cdx2 and
SRD5A2 V89L
444/488
Non-Hispanic White
(NHW) men
141/273
Hispanic White (HW) men
Prostate cancer risk was increased by the interaction
of the genotype with VDR SRD5A2 V89L VV FokI
TT/CT genotypes in NHW men and the interaction of
the SRD5A2 V89L VV genotype with VDR CDX2 GG
genotypes in HW men [165]
(22)
CYP27A1, GC,
CYP27B1,
CYP24A1, VDR,
7 vitamin D
signalingdownstream
genes
212 SNPs 749/781
No associationwith overall cancer risk except that the
BsmI and rs11574143 were associated with cancer risk
only in men with lower 25(OH)D levels [166]
(23) VDR Fok1,Cdx2,Bsm1,
Apa1, and Taq1
1,604 cases plus a
meta-analysis of 13 studies
The BsmI (bb versus BB +Bb), ApaI (aa versus
AA+Aa), and TaqI (Tt + tt versus TT) SNPs were
determined to be associated with high Gleasone
scores/cancer progression [167]
(24) VDR a meta-analysis of several
cancers
For prostate cancer, Caucasian men with BsmI Bb
would have signiﬁcant reduction in cancer risk
compared with bb genotype. It also concluded that
Fok1 ﬀ would contribute to the increase in cancer risk
compared with FF genotype [168]
(25) VDR Taql, Apal, Bsml, Fok1,
and CDX2
a meta-analysis of 36
studies
The Taql t and Bsml B alleles were found to be
inversely associated with the risk. the Apal a allele was
contributed to the reduction of cancer risk only in
Asian populations, and the Fokl f allele was
contributed to increased cancer risk only in Caucasian
populations [169]
(26)
VDR,
CYP27B1,
CYP24A1
48 SNPs 827/787
No signiﬁcant evidence of associationof any of these
SNPs (including VDR BsmI, TaqI, ApaIa n dFokI) with
overall cancer risk or risk for tumor aggressiveness
was found [170]
(27) VDR FokI, BsmI, Tru9I,
ApaI, and TaqI
122/130
AC h i n e s eH a np o p u l a t i o n
Only BsmI B allele was found to be inversely
associated with cancer risk compared with the b allele
[171]
(28)
VDR,
CYP19A1,
CYP17A1,
and AR
commonSNPs in
VDR, CYP17A1
CYP19A1
CAG repeat in AR
95 Italian heredofamilial
prostate cancer (HFPC)
cases/378 sporadic cancer
Only SNP rs10735810 (VDR1) T/T genotype in exon
4 of and SNP rs731236 (VDR2) T/T genotype in exon
11 of VDR showed positive interaction resulting in
increased cancer risk for the HFPC patients compared
to sporadic cancer [172]
opportunities for further looking into and understanding
very complexed vitamin D pathways for human cancer
prevention. For example, some studies indicated that high
level of serum vitamin D may, instead of decrease, increase
risk of prostate cancer development or progression. The
possible explanation seems to involve in local prostatic
expressionlevelsofthetwovitaminDmetabolizingenzymes,
CYP27B1 and CYP24A1, as discussed above, which can
be regulated by vitamin D, androgens and other dietary
compounds. Potentially, overexpression of CYP24A1 could
induce vitamin D resistance and promote risk for prostate
cancer. Measuring serum vitamin D may not represent
its levels at local tissues. Moreover, there is almost no
information about the regulation and activities of these
enzymes, as well as vitamin D metabolites in normal and
cancerous prostate tissues under the in vivo conditions.
Similarly, there is lacking of comprehensive information of
in vivo VDR-mediated pathways in prostate cancer tissues.
This could involve the interactions of genetic, epigenetic,
and other endogenous and environmental factors at local8 Advances in Preventive Medicine
tissue levels and will present challenges for developing more
sophisticated study designs in the near future.
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